Provided by Tiger Trade Technology Pte. Ltd.

HENGRUI PHARMA

48.200
-1.460-2.94%
Volume:10.03M
Turnover:484.39M
Market Cap:319.90B
PE:35.01
High:49.660
Open:49.660
Low:47.600
Close:49.660
52wk High:94.869
52wk Low:47.600
Shares:6.64B
HK Float Shares:258.00M
Volume Ratio:1.00
T/O Rate:3.89%
Dividend:0.23
Dividend Rate:0.47%
EPS(LYR):1.377
ROE:12.46%
ROA:7.02%
PB:4.25
PE(LYR):35.01
PS:8.75

Loading ...

Hengrui Pharma Spends 6.79 Million Yuan on Share Buyback on August 12

Stock News
·
Aug 12

Jiangsu Hengrui Pharma Secures Clinical Trial Approval for Innovative Multi-Peptide Drug HRS-4729 Injection

Stock News
·
Aug 12

Earning Preview: HENGRUI PHARMA Q2 revenue is expected to increase, and institutional views are cautiously optimistic

Earnings Agent
·
Aug 12

HENGRUI PHARMA: Wellington Management Group LLP Disposes of Shares, Long Position Falls to 6.91%

HK Disclosure
·
Aug 11

Hengrui Pharma's NewCo Partner Debuts on Nasdaq Following Kailera

Deep News
·
Aug 10

AH Share Premium Ranking Summary for August 10

Stock News
·
Aug 10

Hengrui Pharma Gets Nod to Add Fifth Indication for Ivarmacitinib Sulfate Tablets

MT Newswires Live
·
Aug 10

Hong Kong Stocks in Focus: METIS TECHBIO-P (07666) Surges Over 16% in Morning Trade as In-House AiTEM Platform Integrates with Jiangsu Hengrui Pharmaceuticals

Stock News
·
Aug 10

Hengrui Pharma Prioritizes Stable Business Performance to Sustain Long-Term Value and Reward Shareholders

Deep News
·
Aug 07

HENGRUI PHARMA Continues to Reward Shareholders Through Dividends and Other Methods

Deep News
·
Aug 07

Jiangsu Hengrui Pharmaceuticals Focuses on Core Business Growth

Deep News
·
Aug 07

Citigroup's Short Position in H-Shares of Jiangsu Hengrui Pharmaceuticals Decreases to 1.39% on Aug 3 from 2.36% - HKEX

THOMSON REUTERS
·
Aug 07

August 7th A-H Share Premium Data Summary

Stock News
·
Aug 07

HENGRUI PHARMA Shares Surge Over 4% in Late Trading as China's First Anti-HER2 Product for Colorectal Cancer Gains Market Approval

Stock News
·
Aug 07

Movement Alert|HENGRUI PHARMA Rises 3.1% in Regular Trading, Two Innovative Drugs Approved for New Indications

Market Focus
·
Aug 07

Hengrui Pharma Unit Gets Marketing Nod for Colorectal Cancer Drug in China

MT Newswires Live
·
Aug 06

Hengrui Pharma Secures China’s First Anti-HER2 Approval for Colorectal Cancer with Trastuzumab Rezetecan

Bulletin Express
·
Aug 06

Jiangsu Hengrui Pharmaceuticals - Nmpa Approved Additional (Fifth) Indication for Ivarmacitinib Sulfate Tablets (Shr0302 Tablets)

THOMSON REUTERS
·
Aug 06

Jiangsu Hengrui Pharmaceuticals - Nmpa Approves Third Indication for Trastuzumab Rezetecan for Injection for Marketing in China

THOMSON REUTERS
·
Aug 06

JAK1 Inhibitor Aisuda Secures Fifth Indication Approval for Active Non-Radiographic Axial Spondyloarthritis

Deep News
·
Aug 06